Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 118.53% | 104.55% | 46.29% | 10.15% | -4.07% |
| Total Depreciation and Amortization | 14.91% | 12.30% | 22.95% | 29.16% | 50.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.23% | -0.42% | 21.42% | 16.32% | 14.47% |
| Change in Net Operating Assets | -143.50% | -89.70% | 26.12% | 134.31% | 236.90% |
| Cash from Operations | 145.43% | 159.20% | 195.88% | 41.18% | 34.61% |
| Capital Expenditure | 42.79% | 62.73% | 79.06% | 77.69% | 72.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,294.42% | -267.96% | -137.54% | -86.18% | -86.13% |
| Cash from Investing | -4,831.30% | -297.29% | -150.06% | -96.40% | -109.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.49% | 1,849.96% | 2,029.33% | 122.75% | 137.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -104.21% | 74.24% | 74.24% | 10,455.09% | 7,340.14% |
| Cash from Financing | -99.20% | 255.92% | 259.71% | 442.60% | 481.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.28% | -144.65% | 33.03% | 223.72% | 208.23% |